EU-funded researchers gain insights into genetics of lung functioning

A large-scale study has identified five new genetic loci (points on the genome) associated with the health of the human lung and pulmonary function. Publishing in the latest edition of the journal Nature Genetics, the partly EU-funded researchers explain that their findings shed new light on the molecular basis of lung disease and might lead to better treatment of chronic obstructive pulmonary disease (COPD), asthma and similar conditions.

The researchers studied samples from more than 20,000 people, mapping specific loci linked to two clinically relevant measures of lung function. Those measures are forced expiratory volume in the first second (FEV1), which represents the amount of air that can be exhaled in the first second, and the ratio of FEV1 to forced vital capacity (FVC). FVC stands for the amount of air that can be exhaled after full inspiration.

From a clinical point of view, both measures are important indicators of population morbidity and mortality and form the diagnostic basis for COPD. It is also a well-known fact that pulmonary function is in part determined by genetic factors. The research, conducted by 96 scientists in Europe and Australia and led by Dr Martin Tobin of the University of Leicester, UK, and the University of Nottingham's Professor Ian Hall, pinpointed five genetic loci that play a role in the functioning of the lungs. These loci were observed in the whole population and were not specific to smokers, for instance.

In addition, three of the loci were also identified in a second study, published in the same edition of Nature Genetics. The work of the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium is based on a different, but equally large set of samples and thus corroborates some of the findings of Dr Tobin and his colleagues.

"This work is important because until now we have known very little about the genetic factors that determine an individual's lung function," the researchers say. "By identifying the genes important in determining lung function, we can start to unravel the underlying mechanisms which control both lung development and lung damage. This will lead to a better understanding of diseases such as ... COPD and asthma. Crucially, it could open up new opportunities to manage and treat patients with lung conditions."

The scientists add: "A large reduction in lung function occurs in ... COPD, which affects around 1 in 10 adults above the age of 40 and is thought to be the 4th most common cause of death worldwide. Smoking is the major risk factor for development of COPD. Lung function and COPD cluster within families, indicating that variations in genes also predispose individuals to reduced lung function."

Both studies were partly funded by the EU through the following projects: EURO BLCS (Biological, clinical and genetic markers of future risk of cardiovascular disease) and GENOMEUTWIN (Genome-wide analyses of European twin and population cohorts to identify genes in common diseases), both funded under the Fifth Framework Programme (FP5); GABRIEL (A multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community) and EUROSPAN (European special populations research network: quantifying and harnessing genetic variation for gene discovery), both supported through the Sixth Framework Programme (FP6); and GEFOS (Genetic factors for osteoporosis), a project that is part of the Seventh Framework Programme (FP7).

For further information, please visit:

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...